Published in Expert Rev Vaccines on September 01, 2008
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol (2009) 0.88
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res (2007) 1.92
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys (2004) 1.68
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
The Role of Intralesional Therapies in Melanoma. Oncology (Williston Park) (2016) 1.39
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid (2009) 1.35
Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther (2006) 1.32
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol (2009) 1.04
Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg (2006) 1.00
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res (2009) 0.96
Molecularly targeted therapy for melanoma: current reality and future options. Cancer (2006) 0.96
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs (2007) 0.91
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs (2010) 0.90
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer (2012) 0.88
Management of brain metastases in patients with melanoma. Curr Opin Oncol (2004) 0.88
Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis (2012) 0.87
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res (2002) 0.86
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Ann Surg Oncol (2014) 0.85
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol (2002) 0.85
Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs (2005) 0.82
The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer (2003) 0.82
Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park) (2002) 0.81
Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother (2004) 0.81
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer (2008) 0.80
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer (2008) 0.80
Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration. J Opioid Manag (2011) 0.79
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res (2003) 0.79
Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs (2005) 0.78
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res (2004) 0.78
Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol (2009) 0.78
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer (2009) 0.77
Relevance and necessity of studies on second-line chemotherapy in melanoma. Onkologie (2004) 0.75
Understanding and managing interferon-α-related fatigue in patients with melanoma. Melanoma Res (2012) 0.75
Interleukin-2 and histamine dihydrochloride in metastatic melanoma. J Clin Oncol (2002) 0.75
Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist (2006) 0.75
Targeted Therapies in Cancer - Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation. IDrugs (2005) 0.75
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.75
First International Symposium on Melanoma and Other Cutaneous Malignancies. Expert Opin Biol Ther (2004) 0.75
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition. IDrugs (2005) 0.75
Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. Laryngoscope (2008) 0.75